calcimedica inc glp-1 receptor agonists weight management diabetes treatments GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review Persistently low initiation of GLP-1
Description
Dose increases with GLP-1 medicines are planned, stepwise changes that help your
Expert Opin Pharmacother (2013) 14:228196
doi: 10.1111/dom.12082
Payer Action Plan Monitor the Drug Pipeline: At this time, there is no action that payers need to take
3 Note that this consensus algorithm is a guide and that the clinical management of T2DM should always incorporate the patients unique goals, comorbidities, individual response to therapy, and other factors that may introduce unwanted drug interactions or contraindications to a particular therapy or therapies
DOI: 10.2337/dc10-0482
